This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Featured topics will include in-depth sessions covering non-statin lipid lowering therapies, heart failure with preserved ejection fraction, viability, imaging modalities for the assessment of coronaryarterydisease, and antiplatelet therapy after coronary stenting. Too Many Choices? 24 news here.
The announcement specifically highlighted Philips’ first-of-their-kind… Segmented Wall Motion app – an automated tool for segmental wall motion scoring and identifying disorders such as coronaryarterydisease and cardio-oncology issues.
The new FDA-cleared AI-enabled applications include the industry’s first automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronaryarterydisease and cardio-oncology issues in seconds.
The results advocate for considering PCI as a treatment option for such plaques, potentially expanding the indications for PCI in coronaryarterydisease management. Although there were two CSR embolisation events, no acute coronary syndrome events or deaths occurred in either group.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
105 
Let's personalize your content